, Won Jang
, Yong Hyun Cho
Department of Anesthesiology and Pain Medicine, Seoul Sungsim General Hospital, Seoul, Korea
© 2026 Kosin University College of Medicine.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of interest
No potential conflict of interest relevant to this article was reported.
Funding
None.
Author contributions
Conceptualization: HGP, WJ. Data curation: HGP. Formal analysis: HGP. Investigation: HGP, WJ. Methodology: HGP, WJ. Project administration: HGP. Resources: HGP, YHC. Supervision: WJ. Validation: YHC. Visualization: HGP. Writing–original draft: HGP. Writing–review & editing: HGP, WJ, YHC. All authors have read and approved the final manuscript.
The patient's outpatient baseline was 130–160×10³/µL (institutional reference range, 150–350×10³/µL).
HD, hemodialysis; ORIF, open reduction and internal fixation; NSAID, nonsteroidal anti-inflammatory drug; CRP, C-reactive protein; MPV, mean platelet volume; PT, prothrombin time; INR, international normalized ratio; aPTT, activated partial thromboplastin time; LDH, lactate dehydrogenase; DITP, drug-induced immune thrombocytopenia; Hb, hemoglobin.
Full instrument questionnaires are not reproduced; sources are cited [7,8]. In the Naranjo scale, the +2 for the alternative-cause item reflects the absence of an alternative cause more likely than ceftriaxone, not absolute exclusion; residual diagnostic uncertainty is acknowledged in the text.
CBC, complete blood count; WBC, white blood cell; HIT, heparin-induced thrombocytopenia; DIC, disseminated intravascular coagulation; PT/INR, prothrombin time/international normalized ratio; LDH, lactate dehydrogenase; POD, postoperative day; NSAID, nonsteroidal anti-inflammatory drug; DITP, drug-induced immune thrombocytopenia; PF4, platelet factor 4.
DITP, drug-induced immune thrombocytopenia; MPV, mean platelet volume; LDH, lactate dehydrogenase; PT/INR, prothrombin time/international normalized ratio; aPTT, activated partial thromboplastin time; DIC, disseminated intravascular coagulation; POD, postoperative day; PF4, platelet factor 4; CRP, C-reactive protein; WBC, white blood cell count.
| Study | Age/sex | Renal status | Latency; nadir | Course and outcome |
|---|---|---|---|---|
| Piedra Abusharar et al. [15] (2019) | 71/F | Normal | Approximately 6 day; <1×10³/µL | Antibody-confirmed; recovery after discontinuation; survived. |
| Plas et al. [14] (2025) | Adult | Normal (miliary tuberculosis) | Several days; severe | Antibody-confirmed as ceftriaxone (not tuberculostatics); culprit identification preserved first-line anti-TB therapy; survived. |
| Kumar et al. [17] (2021) | Adult | Normal (meningoencephalitis) | Several days; severe | Recovery after switch to ampicillin; survived. |
| Aryal et al. [16] (2025) | Adult | Not specified (sepsis) | Approximately 1 wk; 18×10³/µL | Antibody-confirmed; initially treated as HIT before DITP confirmed; diagnostic confusion. |
| Sharma et al. [6] (2021) | 62/F | ESRD on hemodialysis | Approximately 12 day; 5×10³/µL | Delayed recovery (approximately 9 days); survived. |
| Jacquot et al. [18] (2013) | 65/F | Hepatic and renal insufficiency | Approximately 7 day; approximately 3×10³/µL | Persistent thrombocytopenia; fatal. |
| Present case | 68/F | ESRD on maintenance hemodialysis | 4 day; 3×10³/µL | Early recovery; sustained; survived. |
| Time point | Platelet (×10³/µL) | Key event and laboratory data |
|---|---|---|
| Preoperative year | 130–160 | Stable baseline during maintenance hemodialysis. |
| Postoperative day | ||
| 0 | 151 | Heparin-free HD. ORIF under ultrasound-guided femoral and popliteal sciatic nerve blocks; no NSAIDs for analgesia. |
| 1 | Not checked | Central venous catheter inserted; cefazolin prophylaxis ongoing. |
| 2 | 126 | Fever 37.9°C after routine HD (heparin 1,000+500 IU); CRP 14.8 mg/dL; blood culture no growth at 5 days. |
| 3 | Not checked | Ceftriaxone 2 g/day started. |
| 7 (pre-HD, our hospital) | 9 | Abrupt platelet fall before the heparin-anticoagulated HD; hemodynamically stable, no bleeding. |
| 7 (post-HD, our hospital) | 3 | Further decline after heparin-anticoagulated HD (1,000+500 IU); in-house smear: severe platelet decrease, no clumping/schistocytes. Ceftriaxone discontinued; transfer. |
| 7 (tertiary) | <5 | MPV 18.1 fL (↑; reference 7.2–11.1). PT 13.7 sec, INR 1.07 (normal); aPTT 50.0 sec (↑); D-dimer 1.48 µg/mL (↑); LDH 196 U/L and bilirubin normal. Fibrinogen not measured. |
| 8 (tertiary) | 32 | MPV 11.3 fL. Recovery without transfusion. Hematology favored DITP; quinolone recommended. |
| 8 (our hospital) | 11 | Repeat complete blood count; ciprofloxacin started. |
| 9 | 38 | Heparin-free HD. Hematochezia approximately 230 g; Hb 8.2 g/dL (from 10.8). Conservative management; no transfusion. |
| 10 | 66 | Hb 7.9 g/dL; 8 units of platelet concentrates transfused. |
| 11 | 224 | Heparin-free HD. Marked platelet increase. |
| 14 | 241 | Aspirin and clopidogrel resumed; discharged. |
| Follow-up (25 mo) | 123–174 | Stable outpatient counts; no recurrent severe thrombocytopenia. |
| Assessment tool | Result | Case-specific rationale |
|---|---|---|
| Naranjo Adverse Drug Reaction Probability Scale | 7 (probable) | Temporal association with ceftriaxone; recovery after withdrawal; objective confirmation by repeated CBC and smear. The “no alternative causes” item (+2) reflects systematic exclusion: sepsis (negative culture, normal WBC at nadir), HIT (4Ts 2, severe thrombocytopenia before heparin-anticoagulated dialysis), DIC (normal PT/INR, normal LDH/bilirubin), thrombotic microangiopathy (no schistocytes), and concomitant drugs (cefazolin given before the stable POD 2 count; no NSAIDs). Rechallenge and drug-level testing not performed. |
| George criteria for DITP | Probable | Ceftriaxone preceded thrombocytopenia with sustained recovery after withdrawal; other drugs were continued or unlikely by timing; other causes were excluded. Rechallenge not performed (unsafe). |
| 4Ts score for HIT | 2 (low probability) | Extremely low nadir; no thrombosis; severe thrombocytopenia already present before the POD 7 heparin-anticoagulated dialysis; PF4/heparin antibody not tested. |
| Diagnostic consideration | Findings considered | Interpretation |
|---|---|---|
| Ceftriaxone-associated DITP | Abrupt fall 4 days after exposure; nadir <5×10³/µL; rapid recovery without transfusion; elevated MPV; Naranjo 7; George criteria probable. | Clinically probable; not serologically confirmed. |
| Pseudothrombocytopenia | Repeat counts at two laboratories; no platelet clumping on smear. | Excluded. |
| Thrombotic microangiopathy | No schistocytes; normal LDH and bilirubin. Haptoglobin and reticulocytes unavailable. | Unlikely. |
| Disseminated intravascular coagulation | Normal PT/INR; isolated aPTT prolongation and mild D-dimer elevation, presumptive residual heparin; fibrinogen and anti-Xa not measured. | Overt DIC not supported; biochemical exclusion incomplete. |
| Heparin-induced thrombocytopenia | Severe thrombocytopenia before POD 7 dialysis; nadir <10×10³/µL; no thrombosis; 4Ts 2; PF4 antibody not tested. | Low probability. |
| Sepsis-associated thrombocytopenia | Fever/CRP on POD 2; culture no growth at 5 days; normal WBC at nadir; rapid recovery. | Unlikely as primary cause. |
| Cefazolin or other prior drugs | Cefazolin POD 0–2; platelet count 126×10³/µL on POD 2; collapse only after ceftriaxone. | Less likely based on the temporal pattern. |
| Study | Age/sex | Renal status | Latency; nadir | Course and outcome |
|---|---|---|---|---|
| Piedra Abusharar et al. [15] (2019) | 71/F | Normal | Approximately 6 day; <1×10³/µL | Antibody-confirmed; recovery after discontinuation; survived. |
| Plas et al. [14] (2025) | Adult | Normal (miliary tuberculosis) | Several days; severe | Antibody-confirmed as ceftriaxone (not tuberculostatics); culprit identification preserved first-line anti-TB therapy; survived. |
| Kumar et al. [17] (2021) | Adult | Normal (meningoencephalitis) | Several days; severe | Recovery after switch to ampicillin; survived. |
| Aryal et al. [16] (2025) | Adult | Not specified (sepsis) | Approximately 1 wk; 18×10³/µL | Antibody-confirmed; initially treated as HIT before DITP confirmed; diagnostic confusion. |
| Sharma et al. [6] (2021) | 62/F | ESRD on hemodialysis | Approximately 12 day; 5×10³/µL | Delayed recovery (approximately 9 days); survived. |
| Jacquot et al. [18] (2013) | 65/F | Hepatic and renal insufficiency | Approximately 7 day; approximately 3×10³/µL | Persistent thrombocytopenia; fatal. |
| Present case | 68/F | ESRD on maintenance hemodialysis | 4 day; 3×10³/µL | Early recovery; sustained; survived. |
The patient's outpatient baseline was 130–160×10³/µL (institutional reference range, 150–350×10³/µL). HD, hemodialysis; ORIF, open reduction and internal fixation; NSAID, nonsteroidal anti-inflammatory drug; CRP, C-reactive protein; MPV, mean platelet volume; PT, prothrombin time; INR, international normalized ratio; aPTT, activated partial thromboplastin time; LDH, lactate dehydrogenase; DITP, drug-induced immune thrombocytopenia; Hb, hemoglobin.
Full instrument questionnaires are not reproduced; sources are cited [ CBC, complete blood count; WBC, white blood cell; HIT, heparin-induced thrombocytopenia; DIC, disseminated intravascular coagulation; PT/INR, prothrombin time/international normalized ratio; LDH, lactate dehydrogenase; POD, postoperative day; NSAID, nonsteroidal anti-inflammatory drug; DITP, drug-induced immune thrombocytopenia; PF4, platelet factor 4.
DITP, drug-induced immune thrombocytopenia; MPV, mean platelet volume; LDH, lactate dehydrogenase; PT/INR, prothrombin time/international normalized ratio; aPTT, activated partial thromboplastin time; DIC, disseminated intravascular coagulation; POD, postoperative day; PF4, platelet factor 4; CRP, C-reactive protein; WBC, white blood cell count.
Cases are grouped by renal status (normal vs. impaired). F, female; TB, tuberculosis; HIT, heparin-induced thrombocytopenia; DITP, drug-induced immune thrombocytopenia; ESRD, end-stage renal disease.